Login / Signup

Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia.

Erna KristinDwi EndartiLevina Chandra KhoeKartika Widayati Taroeno-HariadiChristina TrijayantiArmansyah ArmansyahSudigdo Sastroasmoro
Published in: Asian Pacific journal of cancer prevention : APJCP (2021)
Using either a healthcare or societal perspective, the addition of bevacizumab for mCRC treatment was considered not cost-effective.
Keyphrases
  • metastatic colorectal cancer
  • healthcare
  • end stage renal disease
  • newly diagnosed
  • chronic kidney disease
  • peritoneal dialysis
  • squamous cell carcinoma
  • health information
  • combination therapy
  • replacement therapy